How Desert Oasis Healthcare is building the future of dementia management. Learn how this Neurotrack partner is transforming care pathways When Desert Oasis Healthcare (DOHC) first partnered with Neurotrack in mid-2024, the goal was straightforward: get the right patients identified sooner. What has unfolded since then is something much bigger - a fully integrated, end-to-end dementia care model that is turning early detection into early intervention at scale. Neurotrack Technologies, Inc. is proud to share new data that tells the story of what's possible when clinical innovation meets organizational commitment. The numbers keep getting better When Neurotrack Technologies, Inc. announced its partnership with DOHC last May, Neurotrack Technologies, Inc. highlighted a 29% increase in dementia diagnosis rates in just four months. That momentum has not slowed. Data presented by DOHC's clinical team at the California Society of Health-System Pharmacists meeting shows a 35% net increase in new dementia cases from the start of 2025 through September - compared to the end of 2024. Year over year, the trajectory is clear: patients who would previously have gone undetected are now being identified and connected to care. This matters enormously in the Coachella Valley, where seniors make up roughly one in three residents (nearly double the California state average), and as national estimates suggest that at least 61% of people living with dementia remain undiagnosed. Screening is only the beginning One of the most exciting developments at DOHC isn't just who is being screened - it's what happens next. The surge in diagnoses driven by Neurotrack's cognitive screening highlighted a critical downstream need: access to specialist-level dementia care. With neurology appointments scarce across the region, DOHC took a bold and creative step, launching a dedicated Dementia Care Clinic staffed by a specialized care team to meet patients where the system had gaps. The results of that clinic, now presented in poster format, are compelling. Of the 134 patients enrolled: * The average time from referral to a first encounter with the care team is just 19.41 days - a meaningful achievement in a region with limited specialist availability. * The care team actively manages medications, initiates referrals to social services and behavioral health, and provides regular follow-up to prevent delays in care. * All-cause acute utilization was lower among enrolled patients (35.1%) compared to those not enrolled in the clinic (38.8%), suggesting the model may be reducing unnecessary healthcare use - though the team appropriately notes that larger sample sizes will be needed to confirm statistical significance. This is coordinated, proactive, patient-centered care at its best. A blueprint for dementia care What DOHC has built is not just a local success story - it's a blueprint. By combining Neurotrack's digital screening with a structured clinical care pathway, they have demonstrated that a primary care medical group can take meaningful ownership of dementia care, even in resource-constrained environments. Their workflow is straightforward to replicate: * Screening happens during routine annual wellness visits using Neurotrack's mobile app, with results integrated directly into the EHR. * Flags trigger warm handoffs to the Dementia Care Clinic, ensuring no patient falls through the cracks after a positive screen. * Ongoing care includes medication management, multimodal interventions, and community resource connections, all within the same integrated system. DOHC continues to screen approximately 20,000 patients per year, saves an average of 10 minutes per patient encounter over pen-and-paper assessments, and delivers Neurotrack's screener in both English and Spanish to serve the diverse community. What's next DOHC's team is already looking ahead. Plans include expanding clinic staffing, strengthening early referral pathways following diagnosis, and developing community partnerships. The clinic is also investing in advanced dementia care specialist training (a signal of just how committed this team is committed to gold-standard care). At Neurotrack, Neurotrack Technologies, Inc. couldn't be prouder to be part of this story. Its mission has always been to transform the detection and care of dementia. Watching its partners pair its technology with the infrastructure to support patient outcomes after detection is what makes this work truly meaningful. If your organization is ready to build a smarter, more comprehensive approach to cognitive care, Neurotrack Technologies, Inc.'d love to talk. Related reading. In Medicare Advantage (MA), few metrics carry as much weight as Star Ratings. Originally introduced... The best way to illustrate the potential impact of the CMS-HCC V28 changes on dementia care is to... The Digital Exam Enables Providers, For The First Time Ever, To Quickly Screen Brain Health During...

Collaboration ensures comprehensive care for mental fuzziness and memory lapses linked to menopauseLOS ALTOS, Calif., March 19, 2024 /PRNewswire/ -- Midi Health , the leading virtual care clinic focused exclusively on women navigating midlife hormonal transition, and Neurotrack , maker of innovative digital cognitive assessments, today announced a first-of-its-kind partnership that will help the nearly three-fourths of women who experience midlife brain fog determine whether their symptoms are linked to menopause or indicative of more severe cognitive impairment.Neurotrack screening test for Midi Health helps discern menopause brain fog from more serious cognitive conditions This 3-minute online test can provide peace of mind for women suffering common menopause-related conditionBrain fog or "Menopause Brain" as it's been called, is a long neglected but widely experienced symptom characterized by mental fuzziness and memory lapses that can rob women of their productivity and confidence in the prime of their lives. It can also be an alarming experience for anyone with a family history of Alzheimer's or dementia. For the vast majority of women, the brain fog experienced during the menopause transition is temporary and resolves over time, but it's important to investigate all cognitive complaints.To tackle this challenge, Midi teamed up with Neurotrack, the leading company developing digital cognitive assessments for more than a decade. Starting this week, Midi Health clinicians can send patients a cognitive screening they can complete on a smartphone, tablet, or desktop computer in about 3 minutes. Results are based on speed and accuracy compared to same-aged peers. Patients who receive a low score or have other indications of illness that could cause cognitive impairment are referred to providers who can provide appropriate evaluation